Crystals of naphthofuran-substituted glutarimide compounds, production method and use thereof
Naphthofuran-substituted glutarimide crystals are developed to target androgen receptors for degradation via PROTAC compounds, addressing the ineffectiveness of current CRPC treatments and providing a stable therapeutic option for prostate cancer.
Patent Information
- Application Number
- JP2025514650
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-29
- Filing Date
- 2023-09-13
- Publication Date
- 2025-09-22
AI Technical Summary
Current treatments for castration-resistant prostate cancer (CRPC) are ineffective in the long term, and there is a need for more targeted approaches to degrade androgen receptors to manage prostate cancer progression.
Development of bifunctional proteolysis-targeting chimera (PROTAC) compounds that recruit endogenous proteins to E3 ubiquitin ligases like cereblon for ubiquitination and subsequent degradation of androgen receptors, utilizing specific crystal forms of naphthofuran-substituted glutarimide compounds.
The crystal forms of naphthofuran-substituted glutarimide compounds demonstrate stable properties and potential for effective drug discovery, offering a therapeutic approach to treat diseases associated with androgen protein degradation, such as prostate cancer.